Texas is currently home to 4882 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
Recruiting
This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Saint Joseph Regional Cancer Center, Bryan, Texas
Conditions: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
ALL
Ages:
All
Trial Updated:
06/24/2025
Locations: Texas Oncology, Dallas, Texas
Conditions: Neoplasms
Clinical Study of Edwards Cardioband FIT Valve Repair System
Recruiting
Clinical Study of the Edwards Cardioband FIT Repair System
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Heart Hospital Baylor Plano, Plano, Texas
Conditions: Tricuspid Regurgitation
MILDĀ® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Precision Regenerative and Functional Medicine, West Lake Hills, Texas
Conditions: Lumbar Spinal Stenosis
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Dell Seton Medical Center at The University of Texas, Austin, Texas
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Recruiting
This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Recruiting
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Site 005, Garland, Texas
Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
A Phase 2b Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Recruiting
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
06/23/2025
Locations: Elligo Health Research, Inc., Austin, Texas
Conditions: Chronic Obstructive Pulmonary Disease
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas
Conditions: Obesity, Overweight, Type 2 Diabetes
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Recruiting
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas, Texas
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
UTSW NORC Pilot Spinal Cord Injury Dietary Program
Recruiting
The goal of this observational study is to learn about the effects of a 9-week dietician-guided program modified from the National Diabetic Prevention Program (modified DPP-diet) in people with spinal cord injury on body composition and insulin sensitivity. The main question it aims to answer is: Does 9 week modified DPP-diet reduce body fat percentage and insulin resistance? Participants will: Have 9 weeks of Telehealth visit with dietician certified in providing DPP. Visit the laboratory b... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/23/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Obesity and Obesity-related Medical Conditions, Spinal Cord Injury, Chronic
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Recruiting
This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Advanced Intrahepatic Cholangiocarcinoma